|
What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation |
Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, Stevens J, Strong M, Cantrell A |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, Stevens J, Strong M, Cantrell A. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. Health Technology Assessment 2014; 18(33): 1-119 Authors' objectives The assessment will address the questions: What is the clinical and cost effectiveness of cytisine compared with varenicline for smoking cessation? Specifically, the assessment will: i) Review evidence on the effectiveness and safety of Cytisine in smoking cessation compared with Varenicline; ii) Develop an economic model to estimate the cost effectiveness of Cytisine in the context of NHS smoking cessation services; and iii) provide recommendations based on value of information analyses as to whether a head to head trial of cytisine and varenicline would represent effective use of resources. The NIHR HTA Programme commissioned this technology assessment report on behalf of the HTA Programme Director. Authors' conclusions On the basis of the evidence included in this review, varenicline and cytisine are both effective interventions to aid smoking cessation when compared with placebo. Cytisine is estimated to be both more clinically effective and cost-effective than varenicline. However, there is uncertainty in the decision, and a head-to-head trial of cytisine and varenicline would appear to be an effective use of resources. Indexing Status Subject indexing assigned by CRD MeSH Alkaloids; Azocines; Quinolizines; Smoking Cessations Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32013001086 Date abstract record published 03/01/2014 |
|
|
|